Clinical Trial

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

Study acronym: PRECEPT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2025 (before its estimated June 18, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-05.
Trial Details
NCT Number NCT07226154
Lead Sponsor City of Hope Medical Center
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 200 participants
Start Date 2024-11-15
Primary Completion 2026-06-18 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2025-11-21